東陽光藥(1558.HK)再創新高 月內累漲30% 12月以後將進入流感高峯季節
格隆匯10月31日丨12月以後將逐步進入流感高峯季節,流感疫苗概念股東陽光藥(1558.HK)已自10月初開始拉開上漲步伐,今日漲勢繼續,現報48.05港元,漲3.56%,盤中創歷史新高價49.3港元,暫成交1.38億港元,最新總市值217億港元。該股月內累漲30%,年內累漲93%。在抗病毒治療領域,尤其是抗流感病毒治療領域,公司擁有可威(磷酸奧司他韋)膠囊劑及顆粒劑。衞健委疾控局副局長賀青華昨日介紹,全國流感疫苗總體供應量充足,目前已供應各地1700多萬劑次,是去年同期的3倍;各地流感接種工作正有序進行,累計接種量超過800萬劑次,是去年同期的2倍。今日A股市場的流感概念股華蘭生物漲2.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.